Goldman Sachs: Raised the target price of Cinda Biotech (01801.HK) to 105.94 Hong Kong dollars, with a rating of "buy"

According to the Wise Wealth APP, Goldman Sachs released a research report stating that it has raised its earnings per share forecast for Shineway Pharmaceutical Group (01801.HK) for the years 2026 to 2028 to be 1.42 yuan, 3.11 yuan, and 4.19 yuan respectively, to reflect better-than-expected sales in the first quarter; the target price has been adjusted from 104.61 Hong Kong dollars to 105.94 Hong Kong dollars; with a "buy" rating. The company's product revenue in the first quarter of this year exceeded 3.8 billion yuan, a year-on-year increase of over 50%, higher than the bank's forecast of around 3.5 billion yuan. The strong growth is mainly driven by the expansion of products such as Marsitide and the products newly included in the national medical insurance catalog.